Human CD20/MS4A1 (DXL625) Antibody is a research-grade biosimilar monoclonal antibody. It is a human IgG antibody. Reactivity: Human. Supplied as a liquid in 0.01M PBS pH 7.4. Applications: ELISA, flow cytometry, functional assays and in vivo research. Endotoxin: < 10 EU/mg. Purity: >95% purity as determined by SDS-PAGE. For research use only.
B-lymphocyte antigen CD20 (MS4A1) is a ~33 kDa protein. B-lymphocyte-specific membrane protein that plays a role in the regulation of cellular calcium influx necessary for the development, differentiation, and activation of B-lymphocytes. Functions as a store-operated calcium (SOC) channel component promoting calcium influx after activation by the B-cell receptor/BCR. CD20 is the therapeutic target of rituximab (MabThera) and obinutuzumab (Gazyva).
Product Name:
Human CD20/MS4A1 (DXL625) Antibody
SKU:
GXBS01023
Size:
100 µg, 1 mg
Antibody Type:
Monoclonal Antibody
Clone:
DXL625
Target:
B-lymphocyte antigen CD20
Isotype:
IgG
Host Species:
Human
Reactivity:
Human
Applications:
ELISA, FCM, Functional assay, Research in vivo
Synonyms:
DXL625
Biological Activity:
DXL625 (1-25 ug/mL; 24 h, 48 h) induces dose-dependent and time-dependent reductions in ATP content in Ramos Burkitt’s lymphoma cells, with greater potency than Rituxan at all tested concentrations (1, 5, 10, 25 ug/mL) after 24 and 48 hours of treatment [1]. DXL625 (1-25 ug/mL; 24 h) induces dose-dependent caspase-mediated apoptosis in Ramos Burkitt’s lymphoma cells, with 30.0% of cells undergoing apoptosis at the highest tested concentration (25 ug/mL) after 24 hours of treatment [1]. DXL625 (10 ug/mL; 24 h) induces caspase-mediated apoptosis in Ramos Burkitt’s lymphoma cells, with 24.2% of cells testing positive for activated caspases after 24 hours of treatment with 10 ug/mL DXL625 [1]. DXL625 (10 ug/mL; 2 h) induces complement-dependent cytotoxicity in Ramos Burkitt’s lymphoma cells, resulting in 56.5% cell death after 2 hours of treatment with 10 ug/mL DXL625 in the presence of 5% (v/v) rabbit complement sera [1]. DXL625 (10 ug/mL; 2 h) retains complement-dependent cytotoxicity activity against primary CD19 + B-lymphocytes from healthy donor peripheral blood lymphocytes, reducing the CD19 + population to 3.1% after 2 hours of treatment with 10 ug/mL DXL625 in the presence of 5% (v/v) rabbit complement sera [1]. DXL625 (10 ug/mL; 24 h) induces enhanced NK cell-mediated antibody-dependent cellular cytotoxicity in Ramos Burkitt’s lymphoma cells, reducing normalized cell viability to 0.56 after 24 hours of treatment with 10 ug/mL DXL625 at a 6:1 effector-to-target ratio [1]. . Reduced cellular ATP content by 36.5%, 46.3%, 48.3%, and 48.5% at concentrations of 1, 5, 10, and 25 ug/mL, respectively, after 48 hours compared to vehicle-treated cells.
Purity:
>95% as determined by SDS-PAGE.
Endotoxin Level:
< 10 EU/mg
Formulation:
0.01M PBS pH 7.4.
State of Matter:
Liquid
Regulatory Status:
For research use only. Not suitable for clinical or therapeutic use.
Product Preparation:
Protein A/G purified from cell culture supernatant.
Storage and Handling:
Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
